PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Molnupiravir - Covid-19
PAD Profile : Molnupiravir - Covid-19
Keywords :
Covid 19, Coronavirus, antivirals
Brand Names Include :
Lagevrio
Traffic Light Status
Status 1 of 2.
Status :
See narrative
Formulations :
- Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Status :
See narrative
Formulations :
- Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Type
Document
Review Date
Guidelines
No guidelines returned.
Other Drugs
- Budesonide
- Sotrovimab
- Remdesivir
- Casirivimab and imdevimab
- Tocilizumab
- Nirmatrelvir with Ritonavir
- Tixagevimab plus cilgavimab
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
07 February 2022
Surrey Heartlands Medicines Optimisation Board (MOB)
DO NOT prescribe in primary care.
This drug is recommended in the treatment of COVID-19 ONLY in line with NHSE commissioning policies which include detail on eligibility and exclusion criteria for:
- Non-hospitalised patients - Refer eligible patients from Surrey Heartlands and Frimley to the East Berkshire Primary Care Covid Medicine Delivery Unit.
- Hospitalised patients – Hospital treatment of those with acute Covid-19 illness OR with hospital onset Covid-19
Associated BNF Codes
05. Infections
05.03.06. Coronavirus